Table 1 Demographic and clinical characteristics of the study sample.
From: Neural substrates of continuous and discrete inhibitory control
Healthy volunteers (N = 57) | Clinical population (N = 435) | p-value | |||
|---|---|---|---|---|---|
Age, M (SD) | 32.2 | (11.2) | 34.6 | (10.5) | 0.11 |
Male, N (%) | 28 | (49%) | 148 | (34%) | 0.04 |
Race/Ethnicity, N (%) | 0.09 | ||||
White | 41 | (72%) | 285 | (69%) | |
American Indian or Alaska Native | 5 | (9%) | 83 | (19%) | |
Black or African American | 2 | (4%) | 28 | (7%) | |
Hispanic | 4 | (7%) | 16 | (4%) | |
Asian or Pacific Islander | 2 | (4%) | 3 | (1%) | |
“Other”, unspecified | 3 | (5%) | 18 | (4%) | |
Years Education, M (SD) | 6.7 | (1.6) | 5.8 | (1.9) | 0.001 |
Income, M (SD) | $57,047 | ($47,508) | $45,422 | ($72,524) | 0.24 |
PHQ-9, M (SD) | 0.82 | (1.20) | 10.34 | (6.17) | <0.001 |
OASIS, M (SD) | 1.12 | (1.39) | 8.32 | (4.40) | <0.001 |
DAST, M (SD) | 0.12 | (0.38) | 3.18 | (3.72) | <0.001 |
SCOFF, M (SD) | 0.09 | (0.29) | 1.00 | (1.26) | <0.001 |
